Eli Lilly and Company (NYSE:LLY) Holdings Decreased by Cardinal Capital Management

Cardinal Capital Management reduced its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 0.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 28,702 shares of the company’s stock after selling 247 shares during the period. Eli Lilly and Company accounts for about 4.0% of Cardinal Capital Management’s investment portfolio, making the stock its largest holding. Cardinal Capital Management’s holdings in Eli Lilly and Company were worth $25,428,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the business. Lynx Investment Advisory bought a new stake in shares of Eli Lilly and Company in the 2nd quarter worth approximately $32,000. LGT Financial Advisors LLC purchased a new position in Eli Lilly and Company during the second quarter valued at $36,000. Cedar Mountain Advisors LLC boosted its holdings in Eli Lilly and Company by 53.3% in the third quarter. Cedar Mountain Advisors LLC now owns 46 shares of the company’s stock worth $41,000 after acquiring an additional 16 shares in the last quarter. Morton Brown Family Wealth LLC grew its stake in shares of Eli Lilly and Company by 45.5% in the second quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock worth $41,000 after acquiring an additional 15 shares during the last quarter. Finally, Unique Wealth Strategies LLC bought a new position in shares of Eli Lilly and Company during the second quarter valued at $45,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 0.1 %

Shares of LLY stock opened at $917.18 on Friday. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. Eli Lilly and Company has a 12 month low of $547.61 and a 12 month high of $972.53. The stock has a market cap of $871.69 billion, a P/E ratio of 135.08, a P/E/G ratio of 2.79 and a beta of 0.42. The company has a 50 day simple moving average of $920.70 and a two-hundred day simple moving average of $856.27.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The firm had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. On average, research analysts expect that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on LLY. Wells Fargo & Company upped their price target on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research note on Friday, August 9th. Citigroup began coverage on shares of Eli Lilly and Company in a research note on Friday, September 13th. They issued a “buy” rating and a $1,060.00 target price on the stock. Berenberg Bank increased their price target on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. Cantor Fitzgerald restated an “overweight” rating and issued a $885.00 price objective on shares of Eli Lilly and Company in a report on Monday, September 16th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $1,025.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, October 3rd. Three research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $986.00.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.